Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

This week, at the J.P. Morgan Healthcare Conference and the Biotech Showcase, discussions underscored the growing focus on ...

AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.

Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...

Northwell Health’s Feinstein Institutes for Medical Research has received a $2.9m grant from the NIH to explore the use of ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

The CDE of China's NMPA has granted BTD to Innovent Biologics' IBI343 as a monotherapy treatment for CLDN18.2-positive PDAC ...